Signal transduction in anaplastic large cell lymphoma cells (ALCL) mediated by the tumor necrosis factor receptor CD30

Leukemia and Lymphoma

Volumn 45, Issue 5, 2004, Pages 1009-1015

  Schneider, Christof ^a   Stöhr, Dagmar ^a   Merz, Hartmut ^b   Hübinger, Gabriele ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

ALCL; Apoptosis; CD30; p38 MAP kinase; Signal transduction; TNF receptor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOSINE TRIPHOSPHATE; CD30 ANTIGEN; CELL CYCLE PROTEIN; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PROCASPASE 3; PROTEIN P21; STRESS ACTIVATED PROTEIN KINASE; TRYPAN BLUE; TUMOR NECROSIS FACTOR RECEPTOR;

ANAPLASTIC CARCINOMA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL ACTIVATION; CELL ACTIVITY; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME DEGRADATION; ENZYME IMMOBILIZATION; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LARGE CELL LYMPHOMA; LEUKEMOGENESIS; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; APOPTOSIS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION; HUMANS; LYMPHOMA, LARGE-CELL, KI-1; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 11144358309     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000149322     Document Type: Article

References (26)

1. Stein, H., Foss, H.D., Dürkop, H., Marafioti, T., Delsol, G., Pulford, K., et al. (2000) "CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features", Blood, 96, 3681-3695.
2. + lymphomas: A distinct molecular genetic subtype of Non-Hodgkin's Lymphoma", British Journal of Haematology, 113, 275-295.
3. Chiarle, R., Podda, A., Prolla, G., Gong, J., Thorbecke, G.J. and Inghirami, G. (1999) "CD30 in normal and neoplastic cells", Clinical Immunology, 90, 157-164. Review.
4. Dürkop, H., Latza, U., Hummel, M., Eitelbach, F., Seed, B. and Stein, H. (1992) "MOlecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease", Cell, 68, 421-427.
5. Drexler, HG., Gignac, SM., von Wasielewski, R., Werner, M. and Dirks, WG. (2000) "PAthobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas", Leukemia, 14(9), 1533-1559.
6. McDonald, P.P., Cassatella, M.A., Bald, A., Maggi, E., Romagnani, S., Gruss, H.J., et al. (1995) "CD30 ligation induces nuclear factor-kappa B activation in human T cell lines", European Journal of Immunology, 25, 2870-2876.
7. Smith, C.A., Gruss, H.J., Davis, T., Anderson, D., Farrah, T., Baker, E., et al. (1993) "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF", Cell, 73, 1349-1360.
8. Tian, Z.G., Longo, D.L., Funakoshi, S., Asai, O., Ferris, D.K., Widmer, M., et al. (1995) "IN vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts", Cancer Research, 55, 5335-5341.
9. Grell, M., Zimmermann, G., Gottfried, E., Chen, C.M., Grunwald, U., Huang, D.C., et al. (1999) "INduction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: A role for TNF-R1 activation by endogenous membrane-anchored TNF", EMBO Journal, 18, 3034-3043.
10. Mir, S.S., Richter, B.W. and Duckett, C.S. (2000) "DIfferential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells", Blood, 96, 4307-4312.
11. Hsu, P.L. and Hsus, S.M. (2000) "AUtocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: Distinction between Hodgkin's disease and anaplastic large cell lymphoma", Laboratory Investigation, 80, 1111-1119.
12. Hübinger, G., Scheffrahn, I., Müller, E., Bai, R., Duyster, J., Morris, S.W., et al. (1999) "THe tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation", Experimental Hematology, 27, 1796-1805.
13. Hübinger, G., Müller, E., Scheffrahn, I., Schneider, C., Hildt, C., Singer, B.B., et al. (2001) "CD30-mediated cell cycle arrest associated with induced expression of p21 CIP1/WAF1 in the anaplastic large cell lymphoma cell line Karpas 299", Oncogene, 20, 590-598.
14. Muta, H., Boise, L.H., Fang, L. and Podack, E.R. (2000) "CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis", Journal of Immunology, 165, 5105-5111.
15. Levi, E., Wang, Z., Petrogiannis-Haliotis, T., Pfeifer, W.M., Kempf, W., Drews, R., et al. (2000) "DIstinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: A possible mechanism for disease progression", Journal of Investigative Dermatology, 115, 1034-1040.
16. Merz, H., Lange, K., Gaiser, T., Müller, A., Kapp, U., Bittner, C., et al. (2002) "CHaracterization of a Novel Human Anaplastic Large Cell Lymphoma Cell Line Tumorigenic in SCID Mice",Leukemia & Lymphoma, 43, 165-172.
17. Friesen, C., Herr, I., Krammer, P.H. and Debatin, K.M. (1996) "INvolvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells", Nature Medicine, 2, 574-577.
18. Stansfeld, A.G., Diebold, J., Kapanci, G., Lennert, K., Mioduszewska, O., Noel, R., et al. (1988) "UPdated Kiel classification for lymphomas", Lancet, 1, 292-603.
19. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K.C., Cleary, M.L., et al. (1994) "A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group", Blood, 84, 1361-1392.
20. Koon, H.B. and Junghans, R.P. (2000) "ANti-CD30 antibody-based therapy", Current Opinion in Oncology, 12, 588-593.
21. Pfeifer, W., Levi, E., Petrogiannis-Haliotis, T., Lehmann, L., Wang, Z. and Kadin, M.E. (1999) "A murine xenograft model for human CD30 + anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1)", American Journal of Pathology, 155, 1353-1359.
22. Schneider, C. and Hübinger, G. (2002) "PLeiotropic signal transduction mediated by human CD30, a member of the tumor necrosis factor receptor (TNFR) family", Leukemia & Lymphoma, 43, 1355-1366.
23. Nakano, H., Shindo, M., Sakon, S., Nishinaka, S., Mihara, M., Yagita, H., et al. (1998) "DIfferential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1", Proceedings of the National Academy of Sciences of the United States of America, 95, 3537-3542.
24. Dadgostar, H. and Cheng, G. (2000) "MEmbrane localization of TRAF 3 enables JNK activation", Journal of Biological Chemistry, 275, 2539-2544.
25. Kashiwada, M., Shirakata, Y., Inoue, J.I., Nakano, H., Okazaki, K., Okumura, K., et al. (1998) "TUmor necrosis factor receptor-associated kinase (ERK) activity in CD40 signaling along a ras-independent pathway", Journal of Experimenal Medicine, 87, 237-244.
26. Hatzoglou, A., Roussel, J., Bourgeade, M.F., Rogier, E., Madry, C., Inoue, J., et al. (2000) "TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase". Journal of Immunology, 165, 1322-1330.